Needham Maintains Buy on AtriCure, Lowers Price Target to $49
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a 'Buy' rating on AtriCure (NASDAQ:ATRC) but lowers the price target from $68 to $49.
November 02, 2023 | 10:32 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, Needham maintains a 'Buy' rating on AtriCure, indicating continued confidence in the company's prospects.
The lowered price target may initially cause some investor concern, potentially leading to short-term price volatility. However, the maintained 'Buy' rating indicates that Needham still sees value in AtriCure, which could help to stabilize the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100